Senti Biosciences Inc

Entry into a Sublease Agreement

On May 7, 2024, we, as the sublandlord, entered into a sublease agreement, or the Sublease, with GeneFab, LLC, as the subtenant for approximately 7,177 rentable square feet, or RSF, of certain space located at our corporate headquarters, Two Corporate Drive, First Floor, South San Francisco, CA 94080. The term of the Sublease will be effective on May 7, 2024, subject to the consent by the landlord, Britannia Biotech Gateway Limited Partnership and will expire April 30, 2027, subject to earlier termination in accordance with the terms of the Sublease. The initial monthly base rent GeneFab will pay is $5.10 per rentable square feet, or RSF, for the first year of the sublease term, increasing to $5.28 per RSF for the second year of the sublease term, and increasing to $5.46 per RSF for the third year of the sublease term. Under the Sublease, GeneFab was granted a right of first refusal to sublease additional space of approximately three thousand RSF of the premise as described in the Sublease under certain conditions. The Sublease contains customary events of default, representations, warranties and covenants. As part of a prior agreement with GeneFab, GeneFab was permitted to access certain portions of the subleased premises.

The foregoing description of the Sublease does not purport to be a complete description of the rights and obligations of the parties thereunder, and is qualified in its entirety by reference to the full text of the Sublease, which we expect to file as an exhibit to our Quarterly Report on Form 10-Q for the fiscal quarter ending June 30, 2024.

Election of Directors

On May 7, 2024, Susan Berland, a member of the Board of Directors of the Company, or the Board, the Audit Committee of the Board and the Compensation Committee of the Board, notified the Board of her resignation as a director of the Company and all committees thereof, effective June 11, 2024. Ms. Berland’s resignation was not a result of any dispute or disagreement with the Board or management of the Company. Effective upon Ms. Berland’s resignation as a director, the size of the Board will be reduced from six members to five members. The Company thanks Ms. Berland for her years of service as a director.

Director and Executive Officer Trading Arrangements

During the first quarter of 2024, none of our directors or officers adopted orterminated any contract, instruction or written plan for the purchase or sale of our securities intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act or any “non-Rule 10b5-1 trading arrangement” (as defined in Item 408(c) of Regulation S-K).